• Collaboration leads to new antibody media
    New antibody media for affinity chromatography has been created by two firms in the industry

Solid Phase Extraction (SPE)

Collaboration leads to new antibody media

Aug 17 2010

Collaboration between antibody-based affinity purification technology provider BAC BV and human proteins provider Octapharma has led to the development of a new affinity ligand for purifying human cell cultures.

G-CSF CaptureSelect is licensed to Octapharma for use in purifying recombinant human granulocyte-colony stimulating factor, or G-CSF.

Kim Bjornstrup, vice-chairman of Octapharma, explains that the two companies' previous work led to the development.

"The start of this collaboration with BAC, in G-CSF, came from the success with our previous collaboration to develop a ligand for the purification of factor IX," the spokesman says.

With the ligand, Octapharma aims to cut the downstream development time needed in order to produce the recombinant protein, as well as raising the overall recovery of the process compared with conventional techniques.

Octapharma was founded in 1983 and has grown to employ more than 4,000 people, with sales in 2009 surpassing the €1 billion (£820 million) benchmark.

Digital Edition

Chromatography Today - Buyers' Guide 2022

October 2023

In This Edition Modern & Practical Applications - Accelerating ADC Development with Mass Spectrometry - Implementing High-Resolution Ion Mobility into Peptide Mapping Workflows Chromatogr...

View all digital editions


Korea Lab 2024

Apr 23 2024 Kintex, South Korea

Korea Chem 2024

Apr 23 2024 Seoul, South Korea

AOCS Annual Meeting & Expo

Apr 28 2024 Montreal, Quebec, Canada

SETAC Europe

May 05 2024 Seville, Spain

ChemUK 2024

May 15 2024 Birmingham, UK

View all events